BACKGROUND: Anti-angiogenic treatment in recurrent glioblastoma patients suppresses contrast enhancement and reduces vasogenic edema while non-enhancing tumor progression is common. Thus, the importance of T2-weighted imaging is increasing. We therefore quantified T2 relaxation times, which are the basis for the image contrast on T2-weighted images. METHODS: Conventional and quantitative MRI procedures were performed on 18 patients with recurrent glioblastoma before treatment with bevacizumab and every 8 weeks thereafter until further tumor progression. We segmented the tumor on conventional MRI into 3 subvolumes: enhancing tumor, non-enhancing tumor, and edema. Using coregistered quantitative maps, we followed changes in T2 relaxation time in each subvolume. Moreover, we generated differential T2 maps by a voxelwise subtraction using the first T2 map under bevacizumab as reference. RESULTS: Visually segmented areas of tumor and edema did not differ in T2 relaxation times. Non-enhancing tumor volume did not decrease after commencement of bevacizumab treatment but strikingly increased at progression. Differential T2 maps clearly showed non-enhancing tumor progression in previously normal brain. T2 relaxation times decreased under bevacizumab without re-increasing at tumor progression. A decrease of <26 ms in the enhancing tumor following exposure to bevacizumab was associated with longer overall survival. CONCLUSIONS: Combining quantitative MRI and tumor segmentation improves monitoring of glioblastoma patients under bevacizumab. The degree of change in T2 relaxation time under bevacizumab may be an early response parameter predictive of overall survival. The sustained decrease in T2 relaxation times toward values of healthy tissue masks progressive tumor on conventional T2-weighted images. Therefore, quantitative T2 relaxation times may detect non-enhancing progression better than conventional T2-weighted imaging.
BACKGROUND: Anti-angiogenic treatment in recurrent glioblastomapatients suppresses contrast enhancement and reduces vasogenic edema while non-enhancing tumor progression is common. Thus, the importance of T2-weighted imaging is increasing. We therefore quantified T2 relaxation times, which are the basis for the image contrast on T2-weighted images. METHODS: Conventional and quantitative MRI procedures were performed on 18 patients with recurrent glioblastoma before treatment with bevacizumab and every 8 weeks thereafter until further tumor progression. We segmented the tumor on conventional MRI into 3 subvolumes: enhancing tumor, non-enhancing tumor, and edema. Using coregistered quantitative maps, we followed changes in T2 relaxation time in each subvolume. Moreover, we generated differential T2 maps by a voxelwise subtraction using the first T2 map under bevacizumab as reference. RESULTS: Visually segmented areas of tumor and edema did not differ in T2 relaxation times. Non-enhancing tumor volume did not decrease after commencement of bevacizumab treatment but strikingly increased at progression. Differential T2 maps clearly showed non-enhancing tumor progression in previously normal brain. T2 relaxation times decreased under bevacizumab without re-increasing at tumor progression. A decrease of <26 ms in the enhancing tumor following exposure to bevacizumab was associated with longer overall survival. CONCLUSIONS: Combining quantitative MRI and tumor segmentation improves monitoring of glioblastomapatients under bevacizumab. The degree of change in T2 relaxation time under bevacizumab may be an early response parameter predictive of overall survival. The sustained decrease in T2 relaxation times toward values of healthy tissue masks progressive tumor on conventional T2-weighted images. Therefore, quantitative T2 relaxation times may detect non-enhancing progression better than conventional T2-weighted imaging.
Authors: Joonmi Oh; Soonmee Cha; Ashley H Aiken; Eric T Han; Jason C Crane; Jeffrey A Stainsby; Graham A Wright; William P Dillon; Sarah J Nelson Journal: J Magn Reson Imaging Date: 2005-06 Impact factor: 4.813
Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Martin J van den Bent; Michael A Vogelbaum; Patrick Y Wen; David R Macdonald; Susan M Chang Journal: J Clin Oncol Date: 2009-05-18 Impact factor: 44.544
Authors: Whitney B Pope; Jenny H Chen; Jun Dong; Marc R J Carlson; Alla Perlina; Timothy F Cloughesy; Linda M Liau; Paul S Mischel; Phioanh Nghiemphu; Albert Lai; Stanley F Nelson Journal: Radiology Date: 2008-10 Impact factor: 11.105
Authors: E Hattingen; A Jurcoane; M Nelles; A Müller; U Nöth; B Mädler; P Mürtz; R Deichmann; H H Schild Journal: Clin Neuroradiol Date: 2015-07-30 Impact factor: 3.649
Authors: Sen Ma; Christopher T Nguyen; Fei Han; Nan Wang; Zixin Deng; Nader Binesh; Franklin G Moser; Anthony G Christodoulou; Debiao Li Journal: Magn Reson Med Date: 2019-11-25 Impact factor: 4.668
Authors: N Bahrami; D Piccioni; R Karunamuni; Y-H Chang; N White; R Delfanti; T M Seibert; J A Hattangadi-Gluth; A Dale; N Farid; C R McDonald Journal: AJNR Am J Neuroradiol Date: 2018-04-05 Impact factor: 3.825
Authors: Yi Zhang; Xiaoyang Liu; Jinyuan Zhou; Paul A Bottomley Journal: Proc Int Soc Magn Reson Med Sci Meet Exhib Int Soc Magn Reson Med Sci Meet Exhib Date: 2017-04
Authors: Katharina J Wenger; Marlies Wagner; Se-Jong You; Kea Franz; Patrick N Harter; Michael C Burger; Martin Voss; Michael W Ronellenfitsch; Emmanouil Fokas; Joachim P Steinbach; Oliver Bähr Journal: Oncol Lett Date: 2017-05-25 Impact factor: 2.967
Authors: Tonima Sumya Ali; Thorarin Albert Bjarnason; Donna L Senger; Jeff F Dunn; Jeffery T Joseph; Joseph Ross Mitchell Journal: J Med Imaging (Bellingham) Date: 2015-07-21